Monday, October 14, 2024

Novel approach to treating type 2 diabetes shows prolonged normal blood sugar levels after one-time procedure

A novel approach to treating type 2 diabetes is being developed at the American Technion Society. The disease, caused by insulin resistance and reduction of cells’ ability to absorb sugar, is characterized by increased blood sugar levels. Its long-term complications include heart disease, strokes, damage to the retina that can result in blindness, kidney failure, and poor blood flow in the limbs that may lead to amputations. It is currently treated by a combination of lifestyle changes, medication, and insulin injections. However, a study led by professor Shulamit Levenberg, PhD student Rita Beckerman from the Stem Cell and Tissue Engineering Laboratory in the Technion’s Faculty of Biomedical Engineering presents a novel treatment approach, using an autograft of muscle cells engineered to take in sugar at increased rates, reports Medical Xpress. Mice treated in this manner displayed normal blood sugar levels for months after a single procedure. The group’s findings were recently published in Science Advances. After the one treatment, the mice remained cured of diabetes for four months – the entire period they remained under observation. Their blood sugar levels remained lower, and they had reduced levels of fatty liver normally displayed in type 2 diabetes.

 

https://medicalxpress.com/news/2021-10-approach-diabetes-prolonged-blood-sugar.html

BIG Media
BIG Media
Our focus is on facts, accurate data, and logical interpretation. Our only agenda is the truth.
spot_img

BIG Wrap

Spacecraft begins mission to explore mysterious Jupiter moon

(BBC News) A spacecraft that will hunt for signs of life on one of Jupiter’s icy moons has blasted off from Cape Canaveral, Florida. NASA...

Man arrested outside Trump rally had two guns, fake passports

(BBC News) A man armed with guns and a high-capacity magazine was arrested outside Donald Trump's rally in California on Saturday, police say. Vem Miller,...